Head-To-Head Survey: AB Corporate Bond ETF (NASDAQ:EYEG) vs. Clever Leaves (NASDAQ:CLVR)

Volatility and Risk

AB Corporate Bond ETF has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 3784.43, suggesting that its stock price is 378,343% more volatile than the S&P 500.

Earnings & Valuation

This table compares AB Corporate Bond ETF and Clever Leaves”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AB Corporate Bond ETF	$12,059.00	2,339.17	-$8.09 million	($1.68)	-20.99
Clever Leaves	$17.42 million	0.00	-$17.90 million	($12.36)	N/A

AB Corporate Bond ETF has higher earnings, but lower revenue than Clever Leaves. AB Corporate Bond ETF is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AB Corporate Bond ETF and Clever Leaves’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AB Corporate Bond ETF	N/A	-104.96%	-60.03%
Clever Leaves	N/A	N/A	N/A

Insider & Institutional Ownership

64.2% of AB Corporate Bond ETF shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 58.2% of AB Corporate Bond ETF shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Clever Leaves beats AB Corporate Bond ETF on 5 of the 9 factors compared between the two stocks.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

About Clever Leaves

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.